Annual TPD and Induced Proximity Summit on October 27-30, 2025 in Boston, United States

As the TPD field eagerly awaits the approval of Arvinas's Vepdegestrant, and with C4 Therapeutics and Kymera progressing through Phase 1 and 2 clinical trials, 2025 is poised to be the year of clinical validation for TPD. This has been echoed in the flurry of partnerships worth over $200M in 2025 alone, with the majority of big pharma now invested in molecular glues, PROTACs, or novel induced proximity drugs.

Returning as the industry's definitive forum from early discovery to clinical development, the 8th Annual TPD and Induced Proximity Summit is the world's largest and longest-standing forum for proximity-based modalities, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development.

Featuring key leaders such as Arvinas, Nurix Therapeutics, C4 Therapeutics, and innovative newcomers including Larkspur Bio, Magnet Biomedicine, TrimTech Therapeutics, as well as the co-founders of TPD, Craig Crews and Ray Deshaies, this is your ultimate meeting to hear the latest clinical data, forge strategic relationships, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need.

URLs:

Tickets: https://go.evvnt.com/3119070-2?pid=10008

Brochure: https://go.evvnt.com/3119070-3?pid=10008

Time: 7:30 AM - 5:00 PM

Prices:

Drug Developer - Conference + New Frontiers Day + Future of TPD Day: USD 6295.00,

Drug Developer - Conference + Future of TPD Day: USD 4797.00,

Drug Developer - Conference Only : USD 3299.00,

Academic - Conference + New Frontiers Day + Future of TPD Day: USD 5495.00,

Academic - Conference + Future of TPD Day: USD 4197.00,

Academic - Conference Only: USD 2899.00,

Service Provider - Conference + New Frontiers Day + Future of TPD Day: USD 7295.00,

Service Provider - Conference + Future of TPD Day: USD 5597.00,

Service Provider - Conference Only: USD 3899.00,

Drug Developer - Conference + New Frontiers Day: USD 4797.00

Speakers: Craig Crews, John C. Malone Professor of Molecular, Cellular, and Developmental Biology, Yale University, Eric Fisher, Director and Professor, DFCI Center for Protein Degradation and Harvard Medical School, Victor Guallar, ICREA Professor, Barcelona Supercomputing Center, Katherine Donovan, Lead Scientist / Managing Director-Fischer labs, Dana Farber Cancer Institute, Christina Woo, Professor, Harvard Medical School, Zoran Rankovic, Director of Center for Protein Degradation, Institute of Cancer Research, Tinghu Zhang, Senior Scientist, Gray Labs, Stanford University, Hong-yu Li, Professor, Health Science Center at San Antonio, Raymond Deshaies, Former Distinguished Fellow, Amgen, Noah Berkowitz, Chief Medical Officer, Arvinas, Arthur T. Sands, Chief Executive Officer, Nurix Therapeutics, Gwenn Hansen, Chief Scientific Officer, Nurix Therapeutics, Andrew Hirsch, President and Chief Executive Officer, C4 Therapeutics, Antony Mattessich, CEO, Amphista Therapeutics, Louise Modis, Chief Scientific Officer, Amphista Therapeutics, Eyal Attar, Chief Medical Officer, Halda Therapeutics, Greg Verdine, CEO, LifeMine Therapeutics, Neil Torbett, Chief Executive Officer, PhoreMost, Benedict Cross, Chief Technology Officer and Head of Platform, PhoreMost, Adam Davenport, Chief Discovery Officer, Proxygen GmbH, Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics, Joey Azofeifa, CEO, Arpeggio Bio, Dong Kim, Chief Executive Officer, AevisBio Inc., Kate Yen, Founder and Chief Executive Officer, Auron Therapeutics, David Millan, Chief Scientific Officer, Auron Therapeutics, Randolph Lopez, Co-founder and Chief Technology Officer, A-Alpha Bio Inc., Zachary Rosenthal, Founder and Chief Executive Officer, Birdwood Therapeutics, Yong Cang, Chief Scientific Officer and Co-Founder, Degron Therapeutics, Simon Glerup, Cso Draupnir, Bio Aps, Guangdi Wang, Chief Executive Officer, EndoTarget, Shyra Gardai, Chief Scientific Officer, EpiBiologics, Anna Rivkin, Chief Business Officer, Foghorn Therapeutics, Anita Bellail, President and Chief Scientific Officer, HB Therapeutics, Inc., Lawrence Hamann, Co-founder and CEO, Interdict Bio, Krista Goodman, CSO, Larkspur Biosciences, Nan Ji, CEO, PAQ Therapeutics, Hyunsun Jo, CEO, Pin Therapeutics, Brent Meadows, Chief Business Officer, Polymed Biopharmaceuticals, Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics, Giovanni Spagnolli, Chief Technology Officer, Sibylla Biotech srl, Scott Kanner, Associate Director - Platform Development, Stablix, Arnout Schepers, CEO, TenAces Biosciences, Chris Tame, Founder and Chief Executive Officer, Ternary Therapeutics, Nicki Thompson, Chief Executive Officer, Trimtech Therapeutics, Robert Hromas, Dean, Dialectic Therapeutics, Henrik Daub, Chief Scientific Officer, NEOsphere Biotechnologies GmbH, Ryan Potts, Vice President, Amgen Inc., Juliet Williams, Head of Research, Kymera Therapeutics, Mark Noviski, Associate Director, Cell Biology, Nurix Therapeutics, Inc., Matthew Sowa, Vice President of Lead Discovery, C4 Therapeutics, Chris Nasveschuk, Senior Vice-President of Chemical Sciences, C4 Therapeutics Inc, Christopher O'Donnell, Executive Director and Vice President - Business Development, Emerging Sciences and Innovation, Partner, Pfizer, David Barrett, Head, Engineered Small Molecules (ESM), Oncology Research, Astellas Pharma, Matthew Hayward, Vice President of Drug Discovery, Magnet Biomedicine, Aly Jackson, Business Development Leader, Genentech, Ian Churcher, CEO and Founder, Janus Drug Discovery Consulting Ltd, Qi Wan, Principal Scientist, Abbvie, Rene Lemieux, SVP and Head of Research, Avilar Therapeutics, Esther Lee, Associate Director of Medicinal Chemistry, AstraZeneca, Changhoon Ji, Executive Director, AUTOTAC Bio, Catherine Henry, Associate Director, Preclinical R and D, Cullinan Oncology, Jing Liu, Senior Vice President, Cullgen Inc., Wu Du, Senior Vice President - Medicinal Chemistry, Hinova Pharmaceuticals, Maureen Galmes-Spit, VP Research, Laigo Bio, Morgan O'Shea, Medicinal Chemist, Larkspur Biosciences, Minoru Tanaka, Director, Mitsubishi Tanabe Pharma, Lingling Shen, Associate Director of Data Sciences, Novartis AG, Markus Haeberlein, Executive Vice President - Discovery Science, Parabilis Medicines, Takeru Furuya, Principal, Venture, Perceptive Advisors LLC, Feng Wang, Senior Principal Scientist, Pfizer, Prakash Palde, Director - Biophysics, High Throughput Screening and Oncology, Pfizer, Andrew Burritt, Senior Director of Chemistry, Plexium Inc., Peggy Thompson, Vice President and Head of Biology, Plexium Inc., Koichi Ito, Senior Director, Prelude Therapeutics​, Jack Carter, Director of Biology and Pharmacology, Prelude Therapeutics​, Rick Ewing, Vice President and Head of Chemistry, Rapafusyn Pharmaceuticals, Derek Taylor, Head of Structural Biology (Rappta Therapeutics); Professor (Case Western Reserve University), Case Western Reserve University, Sanjiv Shah, Executive Director - Discovery Science, Revolution Medicines, Nicholas Endres, Senior Principal Scientist, Genentech, Xiaoqi Liu, Head of Business Development and Strategic Finance, Degron Therapeutics, Joshua Murtie, Vice President - Biology, Photys Therapeutics, Kristin Riching, R and D Group Leader, Promega Corporation, Michael Drummond, Principal Scientist, Scientific Applications Manager, Chemical Computing Group, Henrik Daub Chief Scientific Officer NEOsphere Biotechnologies GmbH